RETAVASE® (reteplase) for injection
  • IMPORTANT SAFETY
     INFORMATION
  • FULL PRESCRIBING
     INFORMATION
  • MEDICAL
     INFORMATION
Menu
  • Home
  • Efficacy
  • Safety
  • Pharmacology
  • Dosing &
     Administration
  • How to
     Order
  • Contact
RETAVASE® (reteplase) logo
Menu
  • Home
  • Efficacy
  • Safety
  • Pharmacology
  • Dosing &
     Administration
  • How to
     Order
  • Contact

RETAVASE® (reteplase) is a recombinant plasminogen activator which catalyzes the cleavage of endogenous plasminogen to generate plasmin. Plasmin degrades the fibrin matrix of the thrombus, exerting its thrombolytic action.

We're sorry for the error

It looks like we’re experiencing server problems. You can return to Home, review Dosing and Administration, find out How to Order, contact us with any questions you may have, or see the RETAVASE® (reteplase) Full Prescribing Information.

Important Safety Information

RETAVASE® (reteplase) for injection is contraindicated in patients with:

  • Active internal bleeding
  • Recent stroke
  • Recent intracranial or intraspinal surgery or serious head trauma
  • Intracranial neoplasm, arteriovenous malformation, or aneurysm
  • Known bleeding diathesis
  • Severe uncontrolled hypertension

RETAVASE can cause significant and sometimes fatal bleeding. In a trial of 2,965 patients administered RETAVASE, the overall rate of in-hospital, intracranial hemorrhage was 0.8%. Avoid intramuscular injections and other trauma as bleeding from recent puncture sites or other recent trauma may occur.

Hypersensitivity reactions have been reported and signs and symptoms included rash, pruritus, erythema, glossal (tongue) edema, hypotension and respiratory distress. If an anaphylactoid reaction occurs, withhold the second dose of RETAVASE and initiate appropriate therapy.

Cholesterol embolism has been reported in patients treated with thrombolytic agents. Cholesterol embolism may present with livedo reticularis, “purple toe” syndrome, acute renal failure, gangrenous digits, hypertension, pancreatitis, myocardial infarction, cerebral infarction, spinal cord infarction, retinal artery occlusion, bowel infarction, and rhabdomyolysis and can be fatal.

Heparin and RETAVASE are incompatible. Do not administer RETAVASE through an intravenous line containing heparin.

The most common adverse reaction (>5%) is bleeding.

Indication and Usage

RETAVASE is a tissue plasminogen activator (tPA) indicated for treatment of acute ST-elevation myocardial infarction (STEMI) to reduce the risk of death and heart failure.

Limitation of Use: The risk of stroke may outweigh the benefit produced by thrombolytic therapy in patients whose STEMI puts them at low risk for death or heart failure.

Please see Full Prescribing Information.

  • Chiesi USA, Inc.
  • Privacy Policy
  • Terms of Use
  • Full Prescribing Information
  • Contact Us
Chiesi. People and ideas for innovation in healthcare.

RETAVASE® is a registered trademark of Chiesi USA, Inc.
©2023 Chiesi USA, Inc. All rights reserved. PP-R-0026 V4.0

Open

Close

FOR US HEALTHCARE PROFESSIONALS

The information provided in this website is intended for US healthcare professionals only.

I certify that I am a US healthcare professional.

Indication and Usage

RETAVASE® (reteplase) is a tissue plasminogen activator (tPA) indicated for treatment of acute ST-elevation myocardial infarction (STEMI) to reduce the risk of death and heart failure.

Limitation of Use: The risk of stroke may outweigh the benefit produced by thrombolytic therapy in patients whose STEMI puts them at low risk for death or heart failure.